Xinhehua raises HK$262m in Hong Kong IPO
Sichuan Xinhehua raised HK$262m in a Hong Kong IPO priced at HK$40.2 a share, with its retail tranche 2,191 times covered and the stock up about 71% on debut.
What happened
Sichuan Xinhehua Traditional Chinese Medicine Pieces raised HK$262m in its Hong Kong IPO on 11 November, selling 6.52m H shares at HK$40.2 each. The retail tranche was 2,191 times covered and the stock closed its first day up about 71%. Net proceeds were HK$197m.
The numbers
| Item | Figure |
|---|---|
| Gross proceeds | HK$262m |
| Shares sold | 6.52m H shares |
| Offer price | HK$40.2 |
| Retail oversubscription | 2,191 times |
| First-day gain | About 71% |
| Net proceeds | HK$197m |
Why it matters
Xinhehua supplies prepared herbal medicines to hospitals and pharmacies. It is a fragmented market where scale and quality certification matter more than brand, and the listing gives the company capital to expand processing capacity and consolidate smaller suppliers.
The counter-argument is that a 71% first-day jump on a 2,191-times retail book is a liquidity event, not a valuation: retail demand can overshoot and reverse. The more durable signal is that Hong Kong will fund consumption-linked healthcare assets with real revenue, which have priced more conservatively than AI or biotech this year.
What to watch
- Deployment of the HK$197m net proceeds into capacity.
- Any acquisition of smaller suppliers.
- Whether the debut gain holds after the retail book clears.
Original source: Zhitong Finance · 11 Nov 2026
